BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 38321223)

  • 1. Factors Impacting Survival After Transarterial Radioembolization in Patients with Unresectable Intrahepatic Cholangiocarcinoma: A Combined Analysis of the Prospective CIRT Studies.
    Reimer P; Vilgrain V; Arnold D; Balli T; Golfieri R; Loffroy R; Mosconi C; Ronot M; Sengel C; Schaefer N; Maleux G; Munneke G; Peynircioglu B; Sangro B; Kaufmann N; Urdaniz M; Pereira H; de Jong N; Helmberger T
    Cardiovasc Intervent Radiol; 2024 Mar; 47(3):310-324. PubMed ID: 38321223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors impacting survival after transarterial radioembolization in patients with hepatocellular carcinoma: Results from the prospective CIRT study.
    Kolligs F; Arnold D; Golfieri R; Pech M; Peynircioglu B; Pfammatter T; Ronot M; Sangro B; Schaefer N; Maleux G; Munneke G; Pereira H; Zeka B; de Jong N; Helmberger T;
    JHEP Rep; 2023 Feb; 5(2):100633. PubMed ID: 36593888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival.
    Hoffmann RT; Paprottka PM; Schön A; Bamberg F; Haug A; Dürr EM; Rauch B; Trumm CT; Jakobs TF; Helmberger TK; Reiser MF; Kolligs FT
    Cardiovasc Intervent Radiol; 2012 Feb; 35(1):105-16. PubMed ID: 21431970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radioembolization with Yttrium-90 Glass Microspheres as a First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma-A Prospective Feasibility Study.
    Kis B; Shridhar R; Mhaskar R; Gyano M; Frakes JM; El-Haddad G; Choi J; Kim RD; Hoffe SE
    J Vasc Interv Radiol; 2023 Sep; 34(9):1547-1555. PubMed ID: 37210030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Yttrium-90 Transarterial Radioembolization for Chemotherapy-Refractory Intrahepatic Cholangiocarcinoma: A Prospective, Observational Study.
    White J; Carolan-Rees G; Dale M; Patrick HE; See TC; Bell JK; Manas DM; Crellin A; Slevin NJ; Sharma RA
    J Vasc Interv Radiol; 2019 Aug; 30(8):1185-1192. PubMed ID: 31255499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant Yttrium-90 Transarterial Radioembolization with Resin Microspheres Prescribed Using the Medical Internal Radiation Dose Model for Intrahepatic Cholangiocarcinoma.
    Sarwar A; Ali A; Ljuboja D; Weinstein JL; Shenoy-Bhangle AS; Nasser IA; Morrow MK; Faintuch S; Curry MP; Bullock AJ; Ahmed M
    J Vasc Interv Radiol; 2021 Nov; 32(11):1560-1568. PubMed ID: 34454031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Application of Trans-Arterial Radioembolization in Hepatic Malignancies in Europe: First Results from the Prospective Multicentre Observational Study CIRSE Registry for SIR-Spheres Therapy (CIRT).
    Helmberger T; Golfieri R; Pech M; Pfammatter T; Arnold D; Cianni R; Maleux G; Munneke G; Pellerin O; Peynircioglu B; Sangro B; Schaefer N; de Jong N; Bilbao JI; ;
    Cardiovasc Intervent Radiol; 2021 Jan; 44(1):21-35. PubMed ID: 32959085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival and Toxicities after Yttrium-90 Transarterial Radioembolization of Cholangiocarcinoma in the RESiN Registry.
    Robinson TJ; Du L; Matsuoka L; Sze DY; Kennedy AS; Gandhi RT; Kouri BE; Collins ZS; Kokabi N; Grilli CJ; Wang EA; Lee JS; Brown DB
    J Vasc Interv Radiol; 2023 Apr; 34(4):694-701.e3. PubMed ID: 36509236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Yttrium-90 microsphere radioembolization in unresectable intrahepatic cholangiocarcinoma.
    Mosconi C; Cappelli A; Ascanio S; Pettinari I; Modestino F; Renzulli M; Galaverni MC; Cucchetti A; Gramenzi A; Pettinato C; Golfieri R
    Future Oncol; 2017 Jun; 13(15):1301-1310. PubMed ID: 28343412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intrahepatic Cholangiocarcinoma Treated with Transarterial Yttrium-90 Glass Microsphere Radioembolization: Results of a Single Institution Retrospective Study.
    Gangi A; Shah J; Hatfield N; Smith J; Sweeney J; Choi J; El-Haddad G; Biebel B; Parikh N; Arslan B; Hoffe SE; Frakes JM; Springett GM; Anaya DA; Malafa M; Chen DT; Chen Y; Kim RD; Shridhar R; Kis B
    J Vasc Interv Radiol; 2018 Aug; 29(8):1101-1108. PubMed ID: 30042074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resin Versus Glass Microspheres for
    Van Der Gucht A; Jreige M; Denys A; Blanc-Durand P; Boubaker A; Pomoni A; Mitsakis P; Silva-Monteiro M; Gnesin S; Lalonde MN; Duran R; Prior JO; Schaefer N
    J Nucl Med; 2017 Aug; 58(8):1334-1340. PubMed ID: 28082436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors affecting outcomes of Yttrium-90 radioembolization in heavily pretreated patients with intrahepatic cholangiocarcinoma.
    Zhao K; Erinjeri JP; Sotirchos VS; Alexander ES; Moussa AM; Marinelli B; Ziv E; Sofocleous CT; Abou-Alfa GK; Jarnagin WR; Karimi A; Yarmohammadi H
    Abdom Radiol (NY); 2023 Jul; 48(7):2434-2442. PubMed ID: 37145313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival and Toxicities after
    Emmons EC; Bishay S; Du L; Krebs H; Gandhi RT; Collins ZS; O'Hara R; Akhter NM; Wang EA; Grilli C; Brower JS; Peck SR; Petroziello M; Abdel Aal AK; Golzarian J; Kennedy AS; Matsuoka L; Sze DY; Brown DB
    Radiology; 2022 Oct; 305(1):228-236. PubMed ID: 35762890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transarterial Yttrium-90 Radioembolization for Unresectable Intrahepatic Cholangiocarcinoma: A Systematic Review and Meta-Analysis.
    Schartz DA; Porter M; Schartz E; Kallas J; Gupta A; Butani D; Cantos A
    J Vasc Interv Radiol; 2022 Jun; 33(6):679-686. PubMed ID: 35219834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Yttrium-90 Radioembolization in Unresectable Intrahepatic Cholangiocarcinoma: Results of a Multicenter Retrospective Study.
    Bargellini I; Mosconi C; Pizzi G; Lorenzoni G; Vivaldi C; Cappelli A; Vallati GE; Boni G; Cappelli F; Paladini A; Sciuto R; Masi G; Golfieri R; Cioni R
    Cardiovasc Intervent Radiol; 2020 Sep; 43(9):1305-1314. PubMed ID: 32642986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Socioeconomic and Survival Analysis of Radioembolization in Patients with Intrahepatic Cholangiocarcinoma: A Propensity Score-Adjusted Study.
    Wu X; Heller M; Lokken RP; Fidelman N; Lam A
    J Vasc Interv Radiol; 2023 May; 34(5):815-823.e1. PubMed ID: 36693521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modified response evaluation criteria in solid tumors and European Association for The Study of the Liver criteria using delayed-phase imaging at an early time point predict survival in patients with unresectable intrahepatic cholangiocarcinoma following yttrium-90 radioembolization.
    Camacho JC; Kokabi N; Xing M; Prajapati HJ; El-Rayes B; Kim HS
    J Vasc Interv Radiol; 2014 Feb; 25(2):256-65. PubMed ID: 24461131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update of the Bologna Experience in Radioembolization of Intrahepatic cholangiocarcinoma.
    Mosconi C; Cacioppa LM; Cappelli A; Gramenzi AG; Vara G; Modestino F; Renzulli M; Golfieri R
    Technol Cancer Res Treat; 2023; 22():15330338231155690. PubMed ID: 36927302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disease control and failure patterns of unresectable hepatocellular carcinoma following transarterial radioembolization with yttrium-90 microspheres and with/without sorafenib.
    Teyateeti A; Mahvash A; Long J; Abdelsalam M; Avritscher R; Kaseb A; Odisio B; Ravizzini G; Surasi D; Teyateeti A; Macapinlac H; Kappadath SC
    World J Gastroenterol; 2021 Dec; 27(47):8166-8181. PubMed ID: 35068861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Yttrium-90 Radioembolization and Concomitant Systemic Gemcitabine, Cisplatin, and Capecitabine as the First-Line Therapy for Locally Advanced Intrahepatic Cholangiocarcinoma.
    Ahmed O; Yu Q; Patel M; Hwang G; Pillai A; Liao CY; Fung J; Baker T
    J Vasc Interv Radiol; 2023 Apr; 34(4):702-709. PubMed ID: 36521794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.